新华制药：关于董事、高级管理人员薪酬方案的公告

Core Viewpoint - The announcement by Xinhua Pharmaceutical regarding the approval of the 2026 remuneration plan for directors and senior management emphasizes a performance-based compensation structure, with a significant portion tied to company performance and individual achievements [1] Group 1: Compensation Structure - The remuneration plan for non-independent directors includes a basic salary, performance pay, and long-term incentives, with performance pay accounting for no less than 60% of total compensation [1] - Independent directors' allowances will be subject to approval by the shareholders' meeting [1] - Senior management compensation is similarly structured, with a minimum of 60% of total pay linked to performance, and basic salaries paid monthly, while other components are settled post-annual audit [1]